Sweet Hope Research Specialty, Inc. | Hialeah, FL

Research site

(Unclaimed)

Location

7100 West 20th Avenue Suite 411, Hialeah, Florida, United States of America

Site insights

Top conditions

Top treatments

MK-3655-001

BI 706321

Ustekinumab

KPL-404

Upadacitinib

Estradiol

Elagolix

MK-3655

TAK-101

Norethindrone Acetate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 8 total trials

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting

Psoriatic Arthritis

Biological: Placebo

Biological: Risankizumab

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting

Psoriatic Arthritis (PsA)

Biological: Placebo

Biological: Risankizumab

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis (SELECT-AXIS 2)

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.The main objectives o...

Active, not recruiting

Spondyloarthritis

Drug: Placebo

Drug: Upadacitinib

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

This study is open to adults, aged 18-75 years, with moderate to severe Crohn's disease.The purpose of this study is to find out whether BI 706321 co...

Active, not recruiting

Crohn Disease

Drug: ustekinumab

Drug: Placebo

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease...

Enrolling

Celiac Disease

Dietary Supplement: Gluten

Drug: TAK-101

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms